Novavax (NVAX) Misses Q4 EPS by $1.09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Novavax Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
February 28, 2023 4:02 PM ESTAchieved revenues in fourth quarter 2022 of $357 million and full year 2022 of $2.0 billionAppointed John C. Jacobs as President and Chief Executive OfficerUpdated U.S. government agreement to include up to 1.5 million additional doses of Novavax's COVID-19 vaccine for delivery in 2023Expanded Nuvaxovid label in adult booster and adolescent primary seriesInitiated Phase 2 trial of COVID-19-Influenza Combination and stand-alone influenza vaccine candidatesCompany to host conference call today at 4:30 p.m. ET
GAITHERSBURG, Md., Feb. 28, 2023... More
